- Home
- HURN vs MRUS Comparison
HURN vs MRUS Comparison
Compare HURN & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- MRUS
- Stock Information
- Founded
- HURN 2002
- MRUS 2003
- Country
- HURN United States
- MRUS Netherlands
- Employees
- HURN N/A
- MRUS N/A
- Industry
- HURN Professional Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- MRUS Health Care
- Exchange
- HURN Nasdaq
- MRUS Nasdaq
- Market Cap
- HURN 2.6B
- MRUS 2.7B
- IPO Year
- HURN 2004
- MRUS 2016
- Fundamental
- Price
- HURN $142.83
- MRUS $56.07
- Analyst Decision
- HURN Strong Buy
- MRUS Strong Buy
- Analyst Count
- HURN 5
- MRUS 15
- Target Price
- HURN $158.60
- MRUS $88.87
- AVG Volume (30 Days)
- HURN 237.5K
- MRUS 1.6M
- Earning Date
- HURN 04-29-2025
- MRUS 05-07-2025
- Dividend Yield
- HURN N/A
- MRUS N/A
- EPS Growth
- HURN 92.74
- MRUS N/A
- EPS
- HURN 6.67
- MRUS N/A
- Revenue
- HURN $1,525,814,000.00
- MRUS $54,732,000.00
- Revenue This Year
- HURN $11.50
- MRUS $39.00
- Revenue Next Year
- HURN $7.48
- MRUS $7.48
- P/E Ratio
- HURN $21.43
- MRUS N/A
- Revenue Growth
- HURN 8.98
- MRUS 42.77
- 52 Week Low
- HURN $85.35
- MRUS $33.19
- 52 Week High
- HURN $155.00
- MRUS $61.28
- Technical
- Relative Strength Index (RSI)
- HURN 45.40
- MRUS 66.86
- Support Level
- HURN $136.98
- MRUS $49.46
- Resistance Level
- HURN $155.00
- MRUS $56.74
- Average True Range (ATR)
- HURN 4.91
- MRUS 3.37
- MACD
- HURN -1.28
- MRUS 1.57
- Stochastic Oscillator
- HURN 32.46
- MRUS 91.31
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.